Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14679110 | 0.88 | LMNA (0.58) | LMNAMAPTSMN1; SMN2PRSS1CTSG | |
| SCHEMBL2273609 | 0.86 | MAPT (0.56) | CYP2C19ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL2667533 | 0.86 | LMNA (0.56) | LMNACYP2C19SLC22A2SLC22A1ALDH1A1 | |
| SCHEMBL2650933 | 0.85 | MAPT (0.53) | CYP2C19ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL23782641 | 0.85 | HPGD (0.61) | CYP2C19ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL14172931 | 0.85 | MAPT (0.55) | CYP2C19ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL8879612 | 0.85 | MAPT (0.55) | CYP2C19ALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL11432192 | 0.84 | NPC1 (0.67) | LMNACYP2C19SLC22A2SLC22A1ALDH1A1 | |
| SCHEMBL27439930 | 0.84 | PRSS1 (0.71) | LMNACYP2C19ALDH1A1MAPTCYP1A2 | |
| Hydrochloric Acid SCHEMBL2651455 | 0.84 | MAPT (0.52) | CYP2C19ALDH1A1MAPTBLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20040152750-A1 | Novel glucagon antagonists | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | US | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | LMNA 3028/4885CYP2C19 946/4885SLC22A2 883/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | LMNA 3028/4885CYP2C19 946/4885SLC22A2 883/4885 |
| US-20040152750-A1 | Novel glucagon antagonists | GLP1R, GCGR, GIPR | LMNA 4032/4885CYP2C19 4401/4885SLC22A2 2886/4885 |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | LMNA 2457/4885CYP2C19 1582/4885SLC22A2 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.